Clinical Trial for Atopic Dermatitis.

The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring.

The study is seeking participants who:

Are currently or recently pregnant
Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis

All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will consist of pregnant women exposed to abrocitinib during pregnancy. The unexposed group will consistent of pregnant women with moderate-to-severe atopic dermatitis who are not exposed to abrocitinib during pregnancy.

The study will compare the experiences of pregnant women receiving abrocitinib to pregnant women who do not. This will help us determine if abrocitinib is safe during pregnancy.

Participants will take part in this study until their infant is 12 months of age. During this time, the participant's care will be managed no differently than if she was not taking part in this study. Data will be collected through a virtual research coordinating center at enrollment, the end of the second trimester, and pregnancy outcome (live birth or fetal loss). For live-born infants, data on the infants will be collected at 4 and 12 months of age. No additional visits beyond routine care will be required.

Closest Location

To find study locations, use the location search box below.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Atopic Dermatitis

Sex

Female

Age

0+ years

View more eligibility criteria on ClinicalTrials.gov

`

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Who may participate

View locations for this study

Nearest Locations found

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

Who may participate

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?